Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.

ABSTRACT: Natalizumab, a highly effective therapy for relapsing-remitting multiple sclerosis, is associated with a risk of progressive multifocal leukoencephalopathy (PML). The objective of this analysis was to examine factors predicting survival in a large natalizumab-associated PML global population. Patients with natalizumab-associated PML identified through postmarketing surveillance were followed up for up to 24 months using a structured questionnaire completed by treating physicians. Demographic and clinical characteristics, JC viral load, magnetic resonance imaging (MRI) results, and Expanded Disability Status Scale (EDSS) and Karnofsky Performance Scale (KPS) scores were compared in survivors and nonsurvivors. Kaplan-Meier analysis was used to model survival function. Among the 336 patients

SUBMITTER: Dong-Si T 

PROVIDER: S-EPMC4628054 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature